DETROIT, Oct. 2, 2024 /PRNewswire/ -- Ambetter from Meridian, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Michiganders in 34 counties in plan year 2025. Open enrollment for the Health Insurance Marketplace for Michigan runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"With food, gas, utility and housing costs continuing to rise throughout Michigan, many individuals and families are looking for ways to save money and meet their basic needs," said Plan President and Chief Executive Officer Patty Graham. "That's why we are proud to offer Ambetter from Meridian, a budget-friendly, high-quality, comprehensive coverage health plan that fits all ages and stages of life."
Ambetter from Meridian offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is the full list of counties in which Ambetter from Meridian will be offered in 2025:
Michigan residents interested in learning more about Ambetter from Meridian or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/mi/.
About Ambetter from Meridian
Ambetter from Meridian serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Meridian is underwritten by Meridian Health Plan of Michigan, Inc., which is a Qualified Health Plan issuer in Michigan. For more information, visit ambetterhealth.com/en/mi/. This is a solicitation for insurance. For information on your right to receive an Ambetter from Meridian plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhalth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$63.17 |
Daily Change: | 0.56 0.89 |
Daily Volume: | 4,431,476 |
Market Cap: | US$31.890B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load